Yes there likely will be a buyout. Of course there is a thirst. It's a proven drug with proven demand and a captive audience even with the US Market lost.
The only question is price. I believe it won't exceed $5B ($4B after taking into account cash in hand and tax loss carry forwards).
Ray, NVS might be interested in AMRN since it bought out MDCO last year. Where did you hear Yee said "if it doesn't happen by H1 2021, it will be a long slog for this company"?